SCHEMBL215342

SCHEMBL215342

C[CH]c1ccc(OC)c(OC)c1[N+](=O)[O-]

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.51
MEN1 O00255 4/20 0.51
PRMT1 Q99873 1/20 0.45
POLB P06746 3/20 0.45
TDP1 Q9NUW8 3/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
KDM4E B2RXH2 2/20 0.45
CTDSP1 Q9GZU7 1/20 0.45
MAPT P10636 6/20 0.44
ALDH1A1 P00352 5/20 0.44
HPGD P15428 1/20 0.44
NPC1 O15118 2/20 0.44
HTT P42858 2/20 0.44
RAB9A P51151 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
LMNA P02545 1/20 0.44
GAA P10253 1/20 0.44
TUBB4A P04350 1/20 0.42
TUBB P07437 1/20 0.42
TUBA3C P0DPH7 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30105929 0.87 KMT2A (0.51) KMT2AMEN1PRMT1POLBTDP1
SCHEMBL622372 0.87 KMT2A (0.51) KMT2AMEN1PRMT1POLBTDP1
SCHEMBL2547688 0.85 KMT2A (0.50) KMT2AMEN1PRMT1POLBTDP1
SCHEMBL3967506 0.81 KMT2A (0.47) KMT2AMEN1PRMT1POLBTDP1
SCHEMBL27841658 0.79 NFE2L2 (0.56) KMT2AMEN1PRMT1POLBMAPT
SCHEMBL5613611 0.79 MAPT (0.49) KMT2AMEN1PRMT1POLBTDP1
SCHEMBL28009577 0.79 MAPT (0.49) KMT2AMEN1PRMT1POLBTDP1
SCHEMBL27773285 0.78 MEN1 (0.53) KMT2AMEN1PRMT1POLBTDP1
SCHEMBL8136793 0.77 ALDH1A1 (0.52) KMT2AMEN1PRMT1POLBTDP1
SCHEMBL14420116 0.77 TDP1 (0.49) KMT2AMEN1PRMT1POLBTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160264612-A1 MASSIVE PARALLEL METHOD FOR DECODING DNA AND RNA UNIV COLUMBIA (US) 2016-09-15 US claimed
US-20130096015-A1 Massive Parallel Method For Decoding DNA And RNA THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2013-04-18 US claimed
US-7345159-B2 Massive parallel method for decoding DNA and RNA THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2008-03-18 US claimed
EP-1790736-A2 Massive parallel method for decoding DNA and RNA THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2007-05-30 EP claimed
EP-1337541-B1 Massive parallel method for decoding DNA and RNA UNIV COLUMBIA (US) 2007-03-07 EP claimed
US-20040185466-A1 to detect single nucleotide polymorphisms, genetic mutation, gene expression, forensic identification, disease association, DNA/genomic sequencing and translation/transcription analysis; solid phase synthesis THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK. 2004-09-23 US claimed
EP-1337541-A4 MASSIVE PARALLEL METHOD FOR DECODING DNA AND RNA UNIV COLUMBIA (US) 2004-07-14 EP claimed
JP-2004510433-A 2004-04-08 JP claimed
US-6664079-B2 Sequencing nucleic acid; obtain nucleotide sequences, incubate in reaction mixture, apply to solid support, determine nucleotide sequences THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2003-12-16 US claimed
EP-1337541-A2 Massive parallel method for decoding DNA and RNA The Trustees of Columbia University in the City of New York (US) 2003-08-27 EP claimed
US-20020102586-A1 Sequencing nucleic acid; obtain nucleotide sequences, incubate in reaction mixture, apply to solid support, determine nucleotide sequences NATIONAL SCIENCE FOUNDATION 2002-08-01 US claimed
WO-2002029003-A2 MASSIVE PARALLEL METHOD FOR DECODING DNA AND RNA THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2002-04-11 WO claimed
US-11940413-B2 Methods and devices for sequencing nucleic acids in smaller batches IsoPlexis Corporation (US) 2024-03-26 US disclosed
US-20240076731-A1 METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES QIAGEN SCIENCES, LLC 2024-03-07 US disclosed
US-20240060128-A1 METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES QIAGEN WALTHAM, INC. 2024-02-22 US disclosed
US-20230407384-A1 METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES QIAGEN WALTHAM, INC. 2023-12-21 US disclosed
US-6307042-B1 GENERATING NUCLEOTIDE SEQUENCES; PROVIDE SUBSTRATE WAFERS, REMOVE PROTECTED GROUPS, TRANSFER SUBSTRATE WAFERS TO COUPLING STATION, TRANSFER SUBSTRATE WAFER TO ACTIVATION STATION, ANALYZE POLYMER LAYOUTS AFFYMETRIX, INC. 2001-10-23 US disclosed
EP-0950112-A1 PHOTOLABILE POLYMER ARRAY SYNTHESIS METHODS Affymetrix, Inc. (a California Corporation) (US) 1999-10-20 EP disclosed
US-5959098-A ACTIVATING AND COUPLING MONOMERS IN DIFFERENT SELECTED ZONES OF SUBSTRATE FORMING DIFFERENT SEQUENCES IN DIFFERENT AREAS; ACTIVATING BY DIRECTING RADIATION AT SURFACE OF SUBSTRATE WITH FUNCTIONAL GROUPS PROTECTED BY PHOTOLABILE GROUPS AFFYMETRIX, INC. (US) 1999-09-28 US disclosed
WO-1997039151-A1 PHOTOLABILE POLYMER ARRAY SYNTHESIS METHODS AFFYMETRIX, INC. (US) 1997-10-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160264612-A1 MASSIVE PARALLEL METHOD FOR DECODING DNA AND RNA RNGTT, NSUN2, RNMT KMT2A 1012/4885MEN1 2796/4885PRMT1 1769/4885
US-20240076731-A1 METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES NT5C2, NOP2, NT5C3B KMT2A 2928/4885MEN1 344/4885PRMT1 3899/4885
US-20230407384-A1 METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES NT5C2, NOP2, NT5C3B KMT2A 2928/4885MEN1 344/4885PRMT1 3899/4885
US-20240060128-A1 METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES NT5C2, NOP2, NT5C3B KMT2A 2928/4885MEN1 344/4885PRMT1 3899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.